Bcl-xL

Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in Oncology

Retrieved on: 
Tuesday, August 1, 2023

TORONTO and HOUSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the issuance of U.S. Patent No.

Key Points: 
  • TORONTO and HOUSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the issuance of U.S. Patent No.
  • The patent further strengthens Medicenna's intellectual property around its BiSKIT™ (Bifunctional SuperKine for ImmunoTherapy) platform.
  • The patent protects a new method for enhancing fitness, survival and proliferation of cancer killing effector T cells and NK cells.
  • The Company’s Superkine patent estate is currently comprised of 56 granted and 61 pending patent applications.

Zentalis Pharmaceuticals Reports Full Year 2022 Financial Results and Operational Updates

Retrieved on: 
Wednesday, March 1, 2023

"2022 was a year of considerable progress for Zentalis.

Key Points: 
  • "2022 was a year of considerable progress for Zentalis.
  • "We are building on the momentum generated in 2022 with many clinical milestones and new programs planned for 2023.
  • Dr. Roth joins Zentalis with over two decades of biopharmaceutical experience building and executing clinical and operational strategies, successfully advancing the development of multiple investigational therapies in oncology.
  • Cash and Marketable Securities Position: As of December 31, 2022, Zentalis had cash, cash equivalents and marketable securities of $437.4 million.

Aspen Aerogels, Inc. Announces Pricing of Upsized Public Offering of $240 Million of Common Stock

Retrieved on: 
Wednesday, November 30, 2022

NORTHBOROUGH, Mass., Nov. 30, 2022 /PRNewswire/ -- Aspen Aerogels, Inc. (NYSE: ASPN) ("Aspen" or the "Company"), a technology leader in sustainability and electrification solutions, today announced the pricing of an underwritten public offering of 25,263,158 shares of its common stock at a public offering price of $9.50 per share.

Key Points: 
  • NORTHBOROUGH, Mass., Nov. 30, 2022 /PRNewswire/ -- Aspen Aerogels, Inc. (NYSE: ASPN) ("Aspen" or the "Company"), a technology leader in sustainability and electrification solutions, today announced the pricing of an underwritten public offering of 25,263,158 shares of its common stock at a public offering price of $9.50 per share.
  • In addition, the Company has granted the underwriters of the offering a 30-day option to purchase up to an additional 3,789,473 shares of common stock.
  • The gross proceeds to Aspen from this offering are expected to be approximately $240 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Aspen, and excluding any exercise of the underwriters' option to purchase additional shares of common stock.
  • All of the shares in the offering are being sold by Aspen.

Aspen Aerogels, Inc. Announces $100 Million Secured Loan Agreement with General Motors

Retrieved on: 
Tuesday, November 29, 2022

NORTHBOROUGH, Mass., Nov. 29, 2022 /PRNewswire/ -- Aspen Aerogels, Inc. (NYSE: ASPN) ("Aspen" or the "Company"), a technology leader in sustainability and electrification solutions, today announced that its wholly-owned subsidiary, Aspen Aerogels Georgia LLC, together with the Company and Aspen Aerogels Rhode Island, LLC have entered into a definitive loan agreement with General Motors Holdings LLC ("GM"), an affiliate of General Motors (NYSE: GM), for a secured lending commitment of $100 million in connection with Aspen's construction and equipping of its second aerogel manufacturing facility in Statesboro, Georgia. The $100 million of loan proceeds (the "Loan") will be available to Aspen to draw on a periodic basis from January 2023 through September 2023, subject to certain conditions precedent to funding and other financing requirements. The Loan has a maturity date of March 31, 2025 and carries no prepayment penalty.

Key Points: 
  • The $100 million of loan proceeds (the "Loan") will be available to Aspen to draw on a periodic basis from January 2023 through September 2023, subject to certain conditions precedent to funding and other financing requirements.
  • The Loan has a maturity date of March 31, 2025 and carries no prepayment penalty.
  • "Aspen is pleased to add this additional financial dimension to our strong technical and commercial relationship with GM, a relationship we deeply value," noted Donald R. Young, Aspen's President and CEO.
  • Earlier this year, GM named Aspen an Overdrive Award winner as part of GM's 30th Annual Supplier of the Year awards.

UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema

Retrieved on: 
Tuesday, November 1, 2022

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the key safety and efficacy endpoints were met at 24 weeks in the Phase 2 BEHOLD study of UBX1325 in patients with diabetic macular edema (DME). The Company intends to initiate a pivotal study in DME in the second half of 2023.

Key Points: 
  • In addition, patients treated with UBX1325 maintained CST compared to sham-treated patients who demonstrated worsening of CST (i.e., increased retinal thickness) through 24 weeks.
  • Of patients treated with UBX1325, 59.4% did not require anti-VEGF standard of care through 6 months, as compared to only 37.5% of sham-treated patients.
  • Based on the results of this study we believe UBX1325 could lead to significant vision gain while reducing treatment burden for patients.
  • The durable effect weve now observed through 6 months following just a single injection of UBX1325 suggests it could represent a longer-lasting, disease-modifying treatment option for patients.

Aspen Aerogels, Inc. Announces Changes to its Board of Directors

Retrieved on: 
Wednesday, November 2, 2022

NORTHBOROUGH, Mass., Nov. 2, 2022 /PRNewswire/ -- Aspen Aerogels, Inc. (NYSE: ASPN) ("Aspen" or the "Company"), a technology leader in sustainability and electrification solutions, today announced the appointment of Katie Kool to its Board of Directors ("Board").

Key Points: 
  • NORTHBOROUGH, Mass., Nov. 2, 2022 /PRNewswire/ -- Aspen Aerogels, Inc. (NYSE: ASPN) ("Aspen" or the "Company"), a technology leader in sustainability and electrification solutions, today announced the appointment of Katie Kool to its Board of Directors ("Board").
  • Kool was also appointed to the Audit Committee and the Nominating, Governance and Sustainability Committee of the Board.
  • Kool commented, "It is a privilege to join Aspen and serve alongside this accomplished Board of Directors.
  • Separately, the Company is announcing the departure of Robert M. Gervis from Aspen's Board and all committees of the Board, effective November 1, 2022.

Aspen Aerogels, Inc. Reports Third Quarter 2022 Financial Results and Recent Business Developments

Retrieved on: 
Wednesday, October 26, 2022

NORTHBOROUGH, Mass., Oct. 26, 2022 /PRNewswire/ -- Aspen Aerogels, Inc. (NYSE: ASPN) ("Aspen" or the "Company"), a technology leader in sustainability and electrification solutions, today announced financial results for the third quarter of 2022, which ended September 30, 2022, and discussed recent business developments.

Key Points: 
  • NORTHBOROUGH, Mass., Oct. 26, 2022 /PRNewswire/ -- Aspen Aerogels, Inc. (NYSE: ASPN) ("Aspen" or the "Company"), a technology leader in sustainability and electrification solutions, today announced financial results for the third quarter of 2022, which ended September 30, 2022, and discussed recent business developments.
  • Total revenue for the third quarter of 2022 was $36.7 million, compared to $30.4 million in the third quarter last year.
  • Adjusted EBITDA for the third quarter of 2022 was $(23.2) million, compared to $(7.8) million in the third quarter of 2021.
  • A conference call with Aspen management to discuss third quarter 2022 results and recent business developments will be held at 8:30 am ET on October 27, 2022.

Aspen Aerogels, Inc. Schedules Third Quarter 2022 Financial Results Release and Conference Call

Retrieved on: 
Wednesday, October 12, 2022

NORTHBOROUGH, Mass., Oct. 12, 2022 /PRNewswire/ --Aspen Aerogels, Inc. (the "Company") (NYSE: ASPN) today announced that Don Young, President & Chief Executive Officer, and Ricardo Rodriguez, Chief Financial Officer & Treasurer, expect to discuss the Company's financial results for the third quarter ended September 30, 2022, during a conference call scheduled for Thursday, October 27, 2022, at 8:30 a.m.

Key Points: 
  • NORTHBOROUGH, Mass., Oct. 12, 2022 /PRNewswire/ --Aspen Aerogels, Inc. (the "Company") (NYSE: ASPN) today announced that Don Young, President & Chief Executive Officer, and Ricardo Rodriguez, Chief Financial Officer & Treasurer, expect to discuss the Company's financial results for the third quarter ended September 30, 2022, during a conference call scheduled for Thursday, October 27, 2022, at 8:30 a.m.
  • The Company expects to release financial results for the third quarter on Wednesday, October 26, 2022, after the market close.
  • Shareholders and other interested parties may participate in the conference call by dialing 844 200 6205 (domestic) or +1 929-526-1599 (international) and referencing conference ID 252601 a few minutes before 8:30 a.m.
  • Aspen's strategy is to partner with world-class industry leaders to leverage its Aerogel Technology Platform into additional high-value markets.

UNITY Biotechnology Completes Enrollment in Phase 2 ENVISION Study of UBX1325 in Wet Age-related Macular Degeneration

Retrieved on: 
Monday, September 19, 2022

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, has completed enrollment for the ENVISION study, its Phase 2 clinical trial of UBX1325 in patients with wet age-related macular degeneration (AMD). This is an active comparator study, examining the efficacy of two doses of UBX1325 compared to every other month treatment with aflibercept through 24 weeks.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, has completed enrollment for the ENVISION study, its Phase 2 clinical trial of UBX1325 in patients with wet age-related macular degeneration (AMD).
  • This is an active comparator study, examining the efficacy of two doses of UBX1325 compared to every other month treatment with aflibercept through 24 weeks.
  • Following the initial evidence of a treatment effect of UBX1325 in patients with diabetic macular edema (DME), we are excited to assess the safety and efficacy of UBX1325 in patients with wet AMD.
  • ENVISION is a multi-center, randomized, active comparator-controlled, double-masked Phase 2 study designed to evaluate the safety, tolerability, efficacy, and durability of UBX1325 in patients with wet AMD.

Aspen Aerogels to Participate in 15th Annual Cowen Global Transportation & Sustainable Mobility Virtual Conference

Retrieved on: 
Tuesday, September 6, 2022

NORTHBOROUGH, Mass., Sept. 6, 2022 /PRNewswire/ -- Aspen Aerogels, Inc. (NYSE: ASPN) ("Aspen" or the "Company"), a technology leader in sustainability and electrification solutions, today announced that the Company is scheduled to participate in the 15th Annual Cowen Global Transportation & Sustainable Mobility Virtual Conference on Wednesday September 7, 2022.

Key Points: 
  • NORTHBOROUGH, Mass., Sept. 6, 2022 /PRNewswire/ -- Aspen Aerogels, Inc. (NYSE: ASPN) ("Aspen" or the "Company"), a technology leader in sustainability and electrification solutions, today announced that the Company is scheduled to participate in the 15th Annual Cowen Global Transportation & Sustainable Mobility Virtual Conference on Wednesday September 7, 2022.
  • The presentation materials utilized during the conference will be available on the Investor Relations section of Aspen's website at www.aerogel.com .
  • Donald R. Young, President & CEO, and Ricardo C. Rodriguez, Senior VP, CFO and Treasurer, will be hosting one-on-one meetings with investors during the conference.
  • In addition, the conference will feature a Fireside Chat with Messrs. Young and Rodriguez, hosted by Cowen's equity research analyst Jeff Osborne, Managing Director Sustainability & Mobility Technology.